Drug intelligence / Profile preview

tianyun

Development stage: Phase 2
Lead developer: Sino Biopharm
Modality: Small Molecules
Administration: Intravenous

Overview

Tianyun is a generic formulation of colistimethate sodium for injection, a polymyxin antibiotic used primarily to treat serious infections caused by multidrug-resistant Gram-negative bacteria. It disrupts the bacterial cell membrane, leading to cell death. Tianyun was launched in 2021 as China's first colistimethate sodium product for injection[3].

Brand names: tianyun
Other names: colistimethate sodium for injection

Beyond the preview

Go deeper on tianyun.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tianyun.

Explore the full profile